Amycretin
| Clinical data | |
|---|---|
| Other names | NN 9487; NN9487; NNC0487-0111 |
| Identifiers | |
| CAS Number | |
Amycretin (development code NN 9487) is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.[1][2][3][4][5] A subcutaneous injection formulation is being developed in parallel.[6]
The drug's dual mechanism of action, which affects appetite regulation (through the GLP-1 receptor) and metabolism (through the amylin receptor), distinguishes it from existing weight loss medications. It contains two covalently linked peptides that are analogs of GLP-1 and amylin respectively. The oral formulation contains salcaprozate sodium (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate; SNAC) as a permeation enhancer.[6]
Clinical trials
[edit]On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin.[7][8][9]
In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks.[10][11]
Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.[7]
References
[edit]- ^ Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (1 February 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.
- ^ Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug". MarketWatch. Retrieved 11 March 2024.
- ^ Jamaluddin, Aqfan; Gorvin, Caroline M (21 March 2023). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. 70 (4). Bioscientifica. doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (March 2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.
- ^ a b Gasiorek A, Heydorn A, Kirkeby K, Key C, Toubro S, Schefe LH, et al. (September 2024). "Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study". Diabetologia. 67. Springer: S42 – S43.
- ^ a b ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. 7 March 2024. Retrieved 13 March 2024.
- ^ Clinical trial number NCT05369390 for "A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity" at ClinicalTrials.gov
- ^ Clinical trial number NCT06049329 for "A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity" at ClinicalTrials.gov
- ^ "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. 24 January 2025. Retrieved 29 January 2025.
- ^ Clinical trial number NCT06064006 for "A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin" at ClinicalTrials.gov